ABSTRACT
SARS-CoV-2 variants of concern (VOC) have spread throughout the world. In Mexico, VOC B.1.351 has been detected on one occasion and B.1.1.7 several times. We detected lineages B.1.351 and B.1.1.7 in patients who traveled to USA and B.1.1.7 in a patient with no travel history. Article summary lineIntroduction of B.1.351 and B.1.1.7 S ARS-CoV-2 variants in Monterrey, Mexico.
ABSTRACT
SARS-CoV-2 variants of concern (VOC) are a worldwide problem. CAL.20C is considered a VOC and its distribution should be monitored. We detected two CAL.20C variants in Monterrey, Mexico in patients who had no recent travel history. This indicates that this variant is now transmitted locally in Northeast Mexico.
ABSTRACT
BackgroundThe progression and distribution of SARS-CoV-2 is unknown because typically only symptomatic individuals are diagnosed. AimWe evaluated the seroprevalence of anti-SARS-CoV-2 in blood donors in Nuevo Leon, Mexico as a strategy for asymptomatic case detection of COVID-19 and epidemic progression. Methods/MaterialsWe tested 1968 blood donors that attended two regional donation centers in Northeast Mexico from January 1st to August 30, 2020, to identify anti-SARS-CoV-2 IgG by chemiluminescent immunoassay. Additionally, routine tests for donors including Brucella, Chagas, HCV, VDRL, HIV-1, and HBsAg identification were performed. ResultsWe found 77 donors reactive for anti-SARS-CoV-2 IgG (seroprevalence 3.99%) and none of them had reported recent COVID-19 symptoms. Donors aged 18 to 49 years (89.5%) were more likely to be seropositive compared to those aged 50 years or older (10.5%) (P<0.001). Prevalence of antibodies increased each epidemiological (EPI) week, parallel to the report of confirmed cases by RT-PCR, identifying the highest prevalence between EPI week 33 and 35 (10.2% to 19%). The metropolitan area of Monterrey recorded the highest number of cases. Routine tests showed that the prevalence of anti-Brucella was 0.13%, anti-HCV 0.5%, anti-HIV-1-2 0.14%, HBsAg 0.16%, Chagas 0.48% and syphilis 1.06%. ConclusionsThere is a growing trend of seroprevalence over time, parallel to the constantly increasing epidemic curve in our region and it was higher under 49 years of age associated with asymptomatic infection in donors from the Nuevo Leon area. Detection of anti-SARS-CoV-2 in blood donors is a potential tool for tracking the progression and identifying population exposure during the SARS-CoV-2 outbreak.
ABSTRACT
BACKGROUND: Aberrant miRNA expression is associated with the development of several diseases including cervical cancer. Dysregulation of miR-125a-5p is present in a plethora of tumors, but its role in cervical cancer is not well understood. OBJECTIVE: The aim was to analyze the expression profile of miR-125a-5p in tumor and immortal cell lines with further target prediction, validation and function analysis. METHODS: MiR-125a-5p expression was determined by real-time RT-PCR from nine cervical cell lines. In silico tools were used to find target transcripts with an miR-125-5p complementary site within the 3'UTR region. Further target selection was based on gene ontology annotation and ΔG analysis. Target validation was performed by transfection of synthetic miR-125a-5p mimics and luciferase assays. Functional evaluation of miR-125a-5p on migration was performed by transwell migration assays. RESULTS: Differential miR-125a-5p expression was observed between immortal and tumor cells regardless of the human papillomavirus (HPV) content. Thermodynamic and ontological analyses showed Microtubule-Affinity-Regulating Kinase1 (MARK1) as a putative target for miR-125a-5p. An inverse correlation was observed among miR-125a-5p expression and MARK1 protein levels in tumor but not in immortal cells. Luciferase assays showed direct miR-125a-5p regulation over MARK1 through recognition of a predicted target site within the 3'-UTR. HeLa and C-33A cervical tumor cells enhanced migration after transfection with miR-125a-5p mimics and stimulation of cell migration was reproduced by siRNA-mediated inhibition of MARK1. CONCLUSION: The results showed MARK1 as a novel functional target for miR-125a-5p with implications on cell migration of tumor cervical cancer cells.
